Zacks: Viking Therapeutics, Inc. (VKTX) Receives Consensus Rating of “Strong Buy” from Analysts

Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) have earned a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy rating.

Brokerages have set a 12-month consensus price target of $7.88 for the company and are predicting that the company will post ($0.19) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Viking Therapeutics an industry rank of 116 out of 265 based on the ratings given to related companies.

VKTX has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Viking Therapeutics in a report on Friday, November 10th. Maxim Group set a $8.00 price target on shares of Viking Therapeutics and gave the company a “buy” rating in a report on Tuesday, November 28th. Roth Capital initiated coverage on shares of Viking Therapeutics in a report on Tuesday, November 21st. They set a “buy” rating and a $5.00 price target for the company. Finally, ValuEngine downgraded shares of Viking Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st.

A number of hedge funds have recently made changes to their positions in the stock. Citadel Advisors LLC bought a new position in shares of Viking Therapeutics in the third quarter worth about $108,000. Virtu KCG Holdings LLC bought a new position in shares of Viking Therapeutics in the second quarter worth about $124,000. Renaissance Technologies LLC raised its stake in shares of Viking Therapeutics by 62.9% in the first quarter. Renaissance Technologies LLC now owns 265,800 shares of the biotechnology company’s stock worth $388,000 after acquiring an additional 102,600 shares during the last quarter. Sabby Management LLC bought a new position in shares of Viking Therapeutics in the second quarter worth about $525,000. Finally, Sphera Funds Management LTD. bought a new position in shares of Viking Therapeutics in the third quarter worth about $554,000. 6.01% of the stock is owned by hedge funds and other institutional investors.

Viking Therapeutics (NASDAQ VKTX) opened at $4.06 on Friday. The company has a market cap of $152.16, a PE ratio of -4.83 and a beta of 1.87. Viking Therapeutics has a 1-year low of $0.88 and a 1-year high of $4.40.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). equities analysts predict that Viking Therapeutics will post -0.86 EPS for the current year.

WARNING: This news story was published by Week Herald and is the sole property of of Week Herald. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://weekherald.com/2017/12/30/zacks-viking-therapeutics-inc-vktx-receives-consensus-rating-of-strong-buy-from-analysts.html.

About Viking Therapeutics

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

Get a free copy of the Zacks research report on Viking Therapeutics (VKTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply